SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Endologix Inc. - ELGX

Levi & Korsinsky announces it has commenced an investigation of Endologix Inc. (NASDAQ:ELGX) ("Endologix") concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On August 2, 2016, CEO John McDermott stated that Endologix would seek approval of the original version of the Nellix system that was used in the Nellix investigational device exemption ("IDE") clinical trial, the EVAS FORWARD-IDE Study, given that Endologix had the needed clinical data. Then on November 16, 2016, Endologix announced that the U.S. Food & Drug Administration requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. When this news was announced, shares of Endologix fell in value. To obtain additional information, go to:

http://zlk.9nl.com/endologix-elgx

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPEduard Korsinsky, Esq.30 Broad Street - 24th FloorNew York, NY 10004Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161117006195/en/
Copyright Business Wire 2010

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains